Editorial
Open access
Sep 2026
Adaptations in pacritinib usage for myelofibrosis and thrombocytopenia since FDA approval
use of pacritinib in transplant-eligible MF patients. The study showed that pacri-tinib provided symptomatic benefit and that its use pre-transplant does not preclude alloHCT.
Valentina Ardila, S. Venugopal
· Expert Review of Hematology · 0 citations